Literature DB >> 24881037

Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.

John Mascarenhas1, Ruben Mesa2, Josef Prchal3, Ronald Hoffman4.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24881037      PMCID： PMC4040888          DOI： 10.3324/haematol.2014.106013

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  34 in total

1.  Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

Authors:  Giovanni Barosi; Ruben Mesa; Guido Finazzi; Claire Harrison; Jean-Jacques Kiladjian; Eva Lengfelder; Mary F McMullin; Francesco Passamonti; Alessandro M Vannucchi; Carlos Besses; Heinz Gisslinger; Jan Samuelsson; Srdan Verstovsek; Ronald Hoffman; Animesh Pardanani; Francisco Cervantes; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

2.  Treatment target in polycythemia vera.

Authors:  Josef T Prchal; Victor R Gordeuk
Journal:  N Engl J Med       Date:  2013-04-18       Impact factor: 91.245

3.  Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

Authors:  Thomas Stauffer Larsen; Katrine F Iversen; Esben Hansen; Anders Bruun Mathiasen; Claus Marcher; Mikael Frederiksen; Herdis Larsen; Inge Helleberg; Caroline Hasselbalch Riley; Ole W Bjerrum; Dorthe Rønnov-Jessen; Michael Boe Møller; Karin de Stricker; Hanne Vestergaard; Hans Carl Hasselbalch
Journal:  Leuk Res       Date:  2013-07-01       Impact factor: 3.156

4.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

5.  Cardiovascular events and intensity of treatment in polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Giorgina Specchia; Rossella Cacciola; Riccardo Cavazzina; Daniela Cilloni; Valerio De Stefano; Elena Elli; Alessandra Iurlo; Roberto Latagliata; Francesca Lunghi; Monia Lunghi; Rosa Maria Marfisi; Pellegrino Musto; Arianna Masciulli; Caterina Musolino; Nicola Cascavilla; Giovanni Quarta; Maria Luigia Randi; Davide Rapezzi; Marco Ruggeri; Elisa Rumi; Anna Rita Scortechini; Simone Santini; Marco Scarano; Sergio Siragusa; Antonio Spadea; Alessia Tieghi; Emanuele Angelucci; Giuseppe Visani; Alessandro Maria Vannucchi; Tiziano Barbui
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

6.  Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

Authors:  S Cortelazzo; P Viero; G Finazzi; A D'Emilio; F Rodeghiero; T Barbui
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

7.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Authors:  Alfonso Quintás-Cardama; Omar Abdel-Wahab; Taghi Manshouri; Outi Kilpivaara; Jorge Cortes; Anne-Laure Roupie; Su-Jiang Zhang; David Harris; Zeev Estrov; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Blood       Date:  2013-06-19       Impact factor: 22.113

8.  A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Authors:  Srdan Verstovsek; Francesco Passamonti; Alessandro Rambaldi; Giovanni Barosi; Peter J Rosen; Elisa Rumi; Elisabetta Gattoni; Lisa Pieri; Paola Guglielmelli; Chiara Elena; Shui He; Nancy Contel; Bijoyesh Mookerjee; Victor Sandor; Mario Cazzola; Hagop M Kantarjian; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Cancer       Date:  2014-02-15       Impact factor: 6.860

9.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors: 
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

10.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528
View more
  5 in total

1.  Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.

Authors:  Lukas Ronner; Nikolai Podoltsev; Jason Gotlib; Mark L Heaney; Andrew T Kuykendall; Casey O'Connell; Jamile Shammo; Angela G Fleischman; Robyn M Scherber; Ruben Mesa; Abdulraheem Yacoub; Cecelia Perkins; Shelby Meckstroth; Lindsey Behlman; Matthew Chiaramonte; Mahta Salehi; Kimia Ziadkhanpour; Hellen Nguyen; Olivia Siwoski; Annie Kwok Hung; Michelle Janania Martinez; Jenny Nguyen; Sagar Patel; Revathi Kollipara; Ami Dave; Megan Randall; Michael Grant; Mitchell Harrison; Paola Fernandez Soto; Douglas Tremblay; Ronald Hoffman; Erin Moshier; John Mascarenhas
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

Review 2.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

Review 3.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

4.  A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Authors:  John Mascarenhas; Heidi E Kosiorek; Josef T Prchal; Alessandro Rambaldi; Dmitriy Berenzon; Abdulraheem Yacoub; Claire N Harrison; Mary Frances McMullin; Alessandro M Vannucchi; Joanne Ewing; Casey L O'Connell; Jean-Jacques Kiladjian; Adam J Mead; Elliott F Winton; David S Leibowitz; Valerio De Stefano; Murat O Arcasoy; Craig M Kessler; Rosalind Catchatourian; Damiano Rondelli; Richard T Silver; Andrea Bacigalupo; Arnon Nagler; Marina Kremyanskaya; Max F Levine; Juan E Arango Ossa; Erin McGovern; Lonette Sandy; Mohamad E Salama; Vesna Najfeld; Joseph Tripodi; Noushin Farnoud; Alexander V Penson; Rona Singer Weinberg; Leah Price; Judith D Goldberg; Tiziano Barbui; Roberto Marchioli; Gianni Tognoni; Raajit K Rampal; Ruben A Mesa; Amylou C Dueck; Ronald Hoffman
Journal:  Blood       Date:  2022-05-12       Impact factor: 25.476

Review 5.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Authors:  Hans Carl Hasselbalch; Mads Emil Bjørn
Journal:  Mediators Inflamm       Date:  2015-10-28       Impact factor: 4.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.